Regimen list

Regimen	Status
- Hypersensitivity - As Required Medications - Version 3	Active
(*riTUXimab), Cyclophosphamide, vinCRIStine and prednisoLONE (*R)-CVP) –21 days - Version 3	Active
(*riTUXimab)-Gemcitabine Cyclophosphamide vinCRIStine and prednisoLONE (* R)- GCVP- 21 days (00737) - Version 2	Active
5-Fluorouracil (4 day) and mitoMYcin Chemoradiation (00451) - Version 6	Active
5-Fluorouracil (5 day) and mitoMYcin Chemoradiation (00450) - Version 4	Active
5-fluorouracil 225mg/m²/day and Radiotherapy (RT)-Continuous infusion (7 day) - Version 6	Active
5-Fluorouracil and Folinic Acid Therapy-14 day Adj - Version 3	Active
5-Fluorouracil and Folinic Acid Therapy-14 day- Met - Version 2	Active
5-Fluorouracil, epiRUBicin 100 and Cyclophosphamide (FEC 100) - Version 2	Active
5-Fluorouracil, epiRUBicin 50 and Cyclophosphamide (FEC 50) (00269) - Version 2	Inactive
Abiraterone 1000mg and Prednisolone 5mg - Version 2	Active
Abiraterone and Prednisolone (00103) - Version 4	Active
ABVD - Version 4	Active
Acalabrutinib Monotherapy - Version 1	Active
Afatinib Monotherapy - Version 2	Active
Aflibercept and FOLFIRI -14 day (00238) - Version 1	Inactive
Alectinib Monotherapy - Version 1	Active
Anastrozole Monotherapy Adj - Version 4	Active
Anastrozole Monotherapy LA/M - Version 3	Active
Apalutamide - Version 1	Active
Atezolizumab 1200mg Monotherapy - Version 2	Active
Atezolizumab 1200mg, CARBOplatin (AUC 5) and Etoposide 100mg/m² - Version 3	Active
Atezolizumab 1680mg Monotherapy – 28 Day (00593) - Version 3	Active
Atezolizumab and nab-PACLitaxel (00688) - Version 5	Active
Avelumab Monotherapy - Version 3	Active
Axitinib Monotherapy - Version 2	Active
azaCITIDine 100mg/m² IV 5-day - Version 1	Active
azaCITIDine 100mg/m² SC 5-day - Version 6	Active
azaCITIDine 75mg/m² IV 5-2-2 - Version 1	Active
azaCITIDine 75mg/m² SC 5-2-2 - Version 6	Active
BEAM Autologous Transplant Conditioning Protocol - Version 2	Active
Bendamustine Monotherapy - Version 2	Active
Bevacizumab 10mg/kg - 14 days (00212) - Version 4	Active
Bevacizumab 10mg/kg and PACLitaxel 80mg/m² - Version 2	Active
Bevacizumab 10mg/kg and PACLitaxel 80mg/m² (Day 1, 8, 15 and 22) (00769) - Version 1	Inactive
Bevacizumab 10mg/kg and Pegylated liposomal DOXOrubicin (CAELYX®) 40mg/m² - Version 1	Inactive
Bevacizumab 10mg/kg and Topotecan 4mg/m² - Version 1	Inactive
Bevacizumab 15mg/kg - 21 days (00215) - Version 5	Active
Bevacizumab 15mg/kg, CARBOplatin (AUC 6) and PACLitaxel 175mg/m² (00766) - Version 1	Active
Bevacizumab 5mg/kg -14 days - Version 2	Inactive
Bevacizumab 5mg/kg and FOLFIRI – 14 days - Version 3	Active
Bevacizumab 5mg/kg and Modified FOLFOX- 6 – 14 days - Version 4	Active
Bevacizumab 7.5mg/kg – 21 days (00214) - Version 4	Active
Bevacizumab 7.5mg/kg and Capecitabine 1250mg/m² Therapy- 21 day (00623) - Version 3	Active
Bevacizumab 7.5mg/kg, CARBOplatin(AUC5) and PACLiltaxel 175mg/m² - Version 3	Active
Bicalutamide - Version 2	Active
Bleomycin, Etoposide and CISplatin (BEP) - Version 2	Active
Bortezomib and Dexamethasone - Version 4	Active
Bortezomib and Lenalidomide (RVD-Lite) Consolidation - Version 1	Active
Bortezomib Maintenance - 14 day - Version 3	Active
Bortezomib, Lenalidomide and Dexamethasone (RVD) - 21 day - Version 3	Active
Bortezomib, Lenalidomide and Dexamethasone (RVD) Therapy - 28 day - Version 2	Active

Regimen list

Regimen	Status
Bortezomib, Lenalidomide and Dexamethasone (RVD-Lite) Induction - Version 1	Active
Bortezomib, Melphalan & Prednisolone - Version 2	Active
Bortezomib, Thalidomide and Dexamethasone (VTD) Induction - Version 2	Active
Bosutinib Monotherapy (00224) - Version 2	Inactive
Brentuximab vedotin and Bendamustine - Version 1	Active
Brentuximab vedotin and ESHAP (BRESHAP) - Version 1	Active
Brentuximab vedotin and ICE - Version 3	Active
Brentuximab vedotin Monotherapy (00234) - Version 4	Active
Brigatinib - Version 3	Active
Busulfan,Cyclophosphamide – MAC – SIB - Version 2	Active
Busulfan,Cyclophosphamide,ATG Grafalon® – MAC – Mismatched Sibling Donor - Version 2	Active
Busulfan,Cyclophosphamide,ATG Grafalon® – MAC – Mismatched Unrelated Donor - Version 2	Active
Busulfan,Cyclophosphamide–MAC–MUD - Version 2	Active
Cabazitaxel and Prednisolone (00101) - Version 2	Active
Cabozantinib - Version 3	Active
Capecitabine 825mg/m² and RT-7 day - Version 3	Active
Capecitabine and Oxaliplatin Therapy (XELOX) Adj (00321.1) - Version 6	Active
Capecitabine and Oxaliplatin Therapy (XELOX) Met (00321.2) - Version 5	Active
Capecitabine and RT – 7 day - Version 5	Active
Capecitabine and Temozolomide - Version 2	Active
Capecitabine Monotherapy Adj (00216.1) - Version 5	Active
Capecitabine Monotherapy LA/M (00216.2) - Version 5	Active
CARBOplatin (AUC 2) Weekly and PACLitaxel (50mg/m²) Weekly with Radiotherapy (RT) -5 weeks - Version 8	Active
CARBOplatin (AUC 2) Weekly with Radiotherapy (RT) - Version 7	Active
CARBOplatin (AUC 3), Etoposide (50mg/m²) and Thoracic Radiotherapy (TRT) -28 day (00561) - Version 3	Active
CARBOplatin (AUC 5) and 5-Fluorouracil 1000mg/m²/day – 28 day - Version 7	Active
CARBOplatin (AUC 6) and PACLitaxel 200mg/m² - Version 6	Active
CARBOplatin (AUC1.5) Chemoradiation - 7 days - Version 6	Active
CARBOplatin (AUC5) and Etoposide 100mg/m² - 21 days - Version 12	Active
CARBOplatin (AUC6) and Weekly PACLitaxel 80mg/m² - Version 3	Active
CARBOplatin (AUC6) and Weekly PACLitaxel 80mg/m² Adj - Version 2	Active
CARBOplatin (AUC6) and Weekly PACLitaxel 80mg/m² followed by Dose Dense DOXOrubicin Cyclophosphamide Therapy- Triple Negative Breast Cancer - Version 5	Active
CARBOplatin 70mg/m² and 5-Fluorouracil 600mg/m² with Radiotherapy - Version 2	Active
CARBOplatin and Oral Etoposide - 21days - Version 6	Active
CARBOplatin and vinORELbine Therapy-21 Day - Version 2	Active
CARBOplatin AUC 4 and 5-Fluorouracil 600mg/m² with Radiotherapy - Version 4	Active
CARBOplatin AUC 5 and Pegylated Liposomal DOXOrubicin 30mg/m² Therapy-28 day - Version 2	Active
CARBOplatin AUC4 Monotherapy-21 days - Version 5	Active
CARBOplatin AUC4 Monotherapy-28 days - Version 5	Active
CARBOplatin AUC5 and PACLitaxel 175mg/m² Adj - Version 6	Active
CARBOplatin AUC5 and PACLitaxel 175mg/m² Met - Version 5	Active
CARBOplatin AUC5 Monotherapy-21 days - Version 5	Active
CARBOplatin AUC5 Monotherapy-28 days - Version 5	Active
CARBOplatin AUC6 and PACLitaxel 175mg/m² Adj - Version 5	Active
CARBOplatin AUC6 and PACLitaxel 175mg/m² Met - Version 6	Active
CARBOplatin AUC6 Monotherapy-21 days - Version 7	Active
CARBOplatin AUC6 Monotherapy-28 days - Version 7	Active
CARBOplatin AUC7 and PACLitaxel 175mg/m² Adj - Version 5	Active
CARBOplatin AUC7 and PACLitaxel 175mg/m² Met - Version 5	Active
CARBOplatin AUC7.5 and PACLitaxel 175mg/m² Adj - Version 7	Active
CARBOplatin AUC7.5 and PACLitaxel 175mg/m² Met - Version 8	Active
Carfilzomib (20/70mg/m² Once weekly) Dexamethasone (Kd) therapy - 28 day - Version 2	Active

Regimen list

Regimen	Status
Carfilzomib (27mg/m² twice weekly), Lenalidomide and Dexamethasone (KRd) - 28 day - Version 4	Active
Carfilzomib (56mg/m² once weekly) Lenalidomide and Dexamethasone (KRd) Therapy - 28 day - Version 2	Active
Carfilzomib and Dexamethasone (Kd) - 28 day - Version 5	Active
Carmustine,Etoposide,Cytarabine,Melphalan,Alemtuzumab RIC-SIB/MUD - Version 2	Active
Ceritinib Monotherapy - Version 1	Active
Cetuximab – 14 days - Version 1	Active
Cetuximab - 7 day (12 weeks) (00207.1) - Version 5	Active
Cetuximab - 7 day (8 weeks) (00207.2) - Version 5	Inactive
Cetuximab (14 days) and FOLFIRI (14 days) - Version 2	Active
Cetuximab (14 days) and Irinotecan (14 days) - Version 3	Active
Cetuximab (7 days) and FOLFIRI (14 days) Therapy - Version 5	Active
Cetuximab (7 days) and Irinotecan (14 days) - Version 3	Active
Cetuximab (weekly), CARBOplatin AUC 5 and 5-Fluorouracil 1000mg/m²/day - 21 day cycle - Version 10	Active
Cetuximab (weekly), CISplatin 100mg/m² and 5-Fluorouracil 1000mg/m²/day - 21 day cycle - Version 6	Active
Cetuximab and FOLFOX-6 (modified) - Version 1	Active
CHI AML MyeChild Course 1 - mitoXANTRONE, Cytarabine and ONE dose gemtuzumab ozogamicin (for patients ≥1 year and >10kg and BSA ≥ 0.5m²) - Version 2	Inactive
CHI AML MyeChild Course 1 - mitoXANTRONE, Cytarabine and THREE dose gemtuzumab ozogamicin (for patients ≥1 year and >10kg and BSA ≥ 0.5m²) - Version 3	Inactive
CHI AML MyeChild Course 1 - mitoXANTRONE, Cytarabine and TWO dose Gemtuzumab Ozogamicin (<1 year or ≤10kg or BSA <0.5m²) - Version 2	Inactive
CHI AML MyeChild Course 2 - FLA IDA (for HR patients <1 year or ≤10kg or BSA <0.5m²) - Version 2	Inactive
CHI AML MyeChild Course 2 – FLA IDA (for HR patients ≥1 year and >10kg and BSA ≥0.5m²) - Version 2	Inactive
CHI AML MyeChild Course 2 - mitoXANTRONE, Cytarabine (for non HR patients <1 year or ≤10kg or BSA <0.5m²) - Version 2	Inactive
CHI AML MyeChild Course 2 - mitoXANTRONE, Cytarabine (for non HR patients ≥1 year and >10kg and BSA ≥0.5m²) - Version 2	Inactive
CHI AML MyeChild Course 3 - FLA (for HR patients ≥1 year and >10kg and BSA ≥0.5m²) - Version 1	Inactive
CHI AML MyeChild Course 3 - FLA (for HR patients <1 year or ≤10kg or BSA <0.5m²) - Version 1	Inactive
CHI AML MyeChild Course 3 - FLA IDA (for IR and HR patients <1 year or ≤ 10kg or BSA <0.5m²) - Version 1	Inactive
CHI AML MyeChild Course 3 - FLA IDA (for IR and HR patients ≥1 year and >10kg and BSA ≥0.5m²) - Version 1	Inactive
CHI AML MyeChild Course 3 and 4 - FLA (for SR patient ≥1 year and >10kg and BSA ≥0.5m²) - Version 1	Inactive
CHI AML MyeChild Course 3 and 4 - FLA (for SR patients <1 year or ≤10kg or BSA <0.5m²) - Version 2	Inactive
CHI AML Myechild Course 3 and 4 - HD Cytarabine (for SR patients <1 year or ≤10kg or BSA <0.5m²) - Version 2	Inactive
CHI AML Myechild Course 3 and 4 - HD Cytarabine (for SR patients ≥1 year and >10kg and BSA ≥0.5m²) - Version 1	Inactive
CHI AML MyeChild Course 4 - High Dose Cytarabine (for IR patients <1 year or ≤10kg or BSA <0.5m2) - Version 1	Inactive
CHI AML MyeChild Course 4 - High Dose Cytarabine (for IR patients ≥1 year and >10kg and BSA ≥0.5m2 - Version 1	Inactive
CHI ES IE/VC Consolidation Euro Ewing 2012 - Version 1	Active
CHI ES VDC/IE Induction Euro Ewing 2012 - Version 3	Active
CHI HBL PHITT Group B (CISplatin with STS Anhydrous) for patients ≥ 10kg - Version 1	Active
CHI HBL PHITT Group C C5VD with STS Anhydrous for patients ≥10kg - Version 1	Active
CHI HBL PHITT Group C CDDP-M (CISplatin with STS Anhydrous) for patients ≥10kg - Version 1	Active
CHI HBL PHITT Group C SIOPEL-3HR with Sodium Thiosulphate Anhydrous for patients ≥10kg - Version 1	Active
CHI HBL PHITT Group D Induction for patients ≥10kg - Version 3	Active

Regimen list

Regimen	Status
CHI HBL PHITT Group D1 Consolidation CARBOplatin and DOXOrubicin (CD) for patients ≥10kg - Version 1	Inactive
CHI HBL PHITT Group D2 Consolidation CD/CE for patients ≥10kg - Version 1	Inactive
CHI HBL PHITT Group D2 Consolidation CD/VI for patients ≥10kg - Version 1	Inactive
CHI HL COPDAC Consolidation (2 cycles) - Version 3	Active
CHI HL COPDAC Consolidation (4 cycles) - Version 3	Inactive
CHI HL DECOPDAC Consolidation (2 cycles) - Version 2	Inactive
CHI HL DECOPDAC Consolidation (4 cycles) - Version 2	Inactive
CHI HL OEPA Induction - Version 2	Active
CHI LCH IV Continuation Arm A for patients ≥10kg - Version 1	Active
CHI LCH IV Continuation Arm B for patients ≥10kg - Version 1	Active
CHI LCH IV Continuation Arm C for patients ≥10kg - Version 1	Active
CHI LCH IV Continuation Arm D for patients ≥10kg - Version 1	Active
CHI LCH IV Stratum 1 Initial course 1 (weekly vinBLAStine) for patients ≥ 10kg - Version 1	Active
CHI LCH IV Stratum 1 Initial course 2 (weekly vinBLAStine) for patients ≥ 10kg - Version 1	Active
CHI LGG Standard Consolidation (patients aged ≥1 year) - Version 2	Active
CHI LGG Standard Consolidation (patients aged 6months – 1 year) - Version 3	Inactive
CHI LGG Standard Consolidation (patients aged less than 6months) - Version 3	Inactive
CHI LGG Standard Induction (patients aged ≥1 year) - Version 2	Active
CHI LGG Standard Induction (patients aged 6months – 1 year) - Version 3	Active
CHI LGG Standard Induction (patients aged less than 6months) - Version 3	Inactive
CHI LGG weekly vinBLAStine (BSA <0.6m2) - Version 3	Active
CHI LGG weekly vinBLAStine (BSA ≥0.6m2) - Version 3	Active
CHI RMS IVA (9 cycles) for patients > 1 year and > 10kg - Version 1	Inactive
CHI RMS VA (8 cycles) for patients >1year and >10kg - Version 1	Inactive
CHI UKALL 2019 Regimen A Maintenance with IT Methotrexate (CHI1144.1) - Version 1	Active
CHI UKALL 2019 Regimen B Maintenance with IT Methotrexate (CHI1145.1) - Version 1	Active
CHI WT Post Op HR-1 (loc) for patients ≥12kg (CCLG Clinical Management Guidelines) - Version 1	Inactive
CHI WT Post Op HRm for patients ≥12kg (CCLG Clinical Management Guidelines). - Version 1	Inactive
Chlorambucil 10mg/m² - Version 2	Active
CHOEP – 21 days - Version 3	Active
CISplatin (100mg/m²) with Radiotherapy (RT) - 21 day - Version 7	Active
CISplatin (40mg/m²) Weekly with Radiotherapy (RT) (5 cycles) (00385.1) - Version 9	Active
CISplatin (40mg/m²) Weekly with Radiotherapy (RT) (6 cycles) (00385.2) - Version 8	Active
CISplatin (50mg/m²) and Etoposide (50mg/m²) and Thoracic Radiotherapy (TRT) -28 day - Version 5	Active
CISplatin (50mg/m²) Chemoradiation followed by CARBOplatin (AUC 5) and PACLitaxel (175mg/m²) – Endometrial Cancer - Version 4	Active
CISplatin (75mg/m²) + Etoposide - 21 day - Version 7	Active
CISplatin (75mg/m²) + Etoposide (100mg/m²) +Thoracic Radiotherapy (TRT) -21 day - Version 6	Active
CISplatin (75mg/m²) + Etoposide (Day 1 IV, Day 2 & 3 Oral) -21 day - Version 1	Active
CISplatin 75mg/m² and 5-Fluorouracil Chemoradiation - Herskovic Regimen - Version 5	Active
CISplatin and 5-Fluorouracil- 28 day cycle - Version 2	Active
CISplatin and Capecitabine Adjuvant Chemoradiation - Version 1	Inactive
CISplatin, 5-Fluorouracil and Radiation Therapy - Version 2	Active
CISplatin, Methotrexate and vinBLAStine (CMV) - Version 2	Active
Cladribine 0.14mg/kg Day 1 to 5 Therapy - Version 3	Active
Cladribine 0.14mg/kg Weekly - Version 4	Active
Cladribine 5 day and riTUXimab - Version 2	Active
Cladribine Weekly and riTUXimab - Version 2	Active

Regimen list

Regimen	Status
COMP- Pembrolizumab in combination with chemotherapy (Nadj) and Pembrolizumab monotherapy (Adj) locally advanced or early stage TNBC high risk of recurrence - Version 1	Active
Crizotinib Monotherapy (00243) - Version 4	Active
Cyclophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 21 Day Adj (00381.1) - Version 6	Active
Cyclophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 21 Day Met (00381.2) - Version 4	Active
Cyclophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 28 day Adj (00378.1) - Version 3	Active
Cyclophosphamide (IV) Methotrexate and 5-Fluorouracil (CMF) 28 Day Met (00378.2) - Version 3	Inactive
Cyclophosphamide (Oral) Methotrexate and 5-Fluorouracil (CMF) Met - Version 2	Active
Cyclophosphamide 1500mg/m² For Stem Cell Mobilisation (00795) - Version 1	Active
Cyclophosphamide 2000mg/m² for Stem Cell mobilisation (high dose cyclophosphamide) (00438) - Version 2	Active
Cyclophosphamide(Oral) Methotrexate and 5-Fluorouracil (CMF) Adj - Version 2	Active
Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) 21-Day - Version 3	Active
Cyclophosphamide, DOXOrubicin and CISplatin Therapy – 21 Day - Version 2	Active
Cyclophosphamide, DOXOrubicin, vinCRIStine and prednisoLONE (CHOP) Therapy– 21 days - Version 2	Active
Cyclophosphamide,Total Body Irradiation (TBI)–MAC–Mismatched Sibling Donor - Version 2	Active
Cyclophosphamide,Total Body Irradiation (TBI)–MAC–Mismatched Unrelated Donor - Version 1	Active
Cyclophosphamide,Total Body Irradiation (TBI)–MAC–MUD - Version 2	Active
Cyclophosphamide,Total Body Irradiation (TBI)–MAC–SIB - Version 2	Active
DA (50/100) (3+8) Course 2 Induction (AML-17) - Version 5	Active
DA(60/100) 3+10: Course 1 Induction (AML-17) - Version 6	Active
Dabrafenib Monotherapy - Version 3	Active
Dacarbazine - Version 1	Active
Dacarbazine (1.2g/m²) -21 day - Version 3	Active
Dacomitinib Monotherapy - Version 1	Active
DACTINomycin - Version 2	Active
Daratumumab (IV), Bortezomib and Dexamethasone Therapy (00560) - Version 3	Active
Daratumumab (SC 1800mg), Bortezomib (weekly) and Dexamethasone Therapy - Version 1	Active
Daratumumab (SC 1800mg), Bortezomib and Dexamethasone - Version 1	Active
Daratumumab (SC), Bortezomib (Once Weekly), Thalidomide and Dexamethasone Consolidation Therapy - Version 2	Active
Daratumumab (SC), Bortezomib (Once Weekly), Thalidomide and Dexamethasone Induction Therapy - Version 1	Active
Daratumumab (SC), Bortezomib, Thalidomide and Dexamethasone Consolidation (00755) - Version 1	Active
Daratumumab (SC), Bortezomib, Thalidomide and Dexamethasone Induction Therapy - Version 2	Active
Daratumumab Monotherapy - Version 4	Active
Daratumumab SC Monotherapy - Version 3	Active
Darolutamide - Version 1	Active
Decitabine Monotherapy - Version 2	Active
Degarelix-28 day - Version 3	Active
Denosumab 120mg - Version 1	Active
Dexamethasone, riTUXimab and Cyclophosphamide (DRC) - Version 2	Active
DOCEtaxel /Cyclophosphamide (TC)-21 day (00250) - Version 6	Active
DOCEtaxel 75mg/m² –Prednisolone Combination - Version 2	Active
DOCEtaxel Monotherapy 100mg/m² - 21 day - Version 3	Active
DOCEtaxel Monotherapy 50mg/m² – 14 day cycle - Version 5	Active
DOCEtaxel Monotherapy 75mg/m² – 21 day cycle (00203) - Version 2	Active
DOCEtaxel, CARBOplatin and Pertuzumab/Trastuzumab (Phesgo®) (TCHP) - Version 1	Active

Regimen list

Regimen	Status
DOCEtaxel, CARBOplatin and Trastuzumab (TCH) - 21 days - Version 7	Active
DOCEtaxel, CARBOplatin, Trastuzumab (SC) and Pertuzumab (TCH(SC) P) – 21 days - Version 2	Active
DOCEtaxel, CARBOplatin, Trastuzumab and Pertuzumab (TCHP) – 21 days - Version 2	Active
DOCEtaxel, CISplatin and 5-Fluorouracil Chemoradiation (Induction) Therapy - Version 3	Active
DOCEtaxel,CISplatin, 5-Fluorouracil and Radiotherapy - Version 3	Active
Dose Adjusted R-EPOCH Dose level 1 (initial dose) (00355.1) - Version 4	Active
Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day (DD AC-T) (00278) - Version 9	Active
Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day and Trastuzumab Therapy (DD AC-TH) - Version 2	Active
Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (80) 7 day (DD AC-T) (00485) - Version 7	Active
Dose Dense DOXOrubicin, Cyclophosphamide (AC60/600) 14 day followed by weekly PACLitaxel and Trastuzumab Therapy (DD AC-TH) - Version 3	Active
DOXOrubicin (25mg/m²/day) and CISplatin (100mg/m²)-21 day cycle-NADJ - Version 2	Active
DOXOrubicin (60) and Ifosfamide - Version 1	Inactive
DOXOrubicin (60mg/m²) - Version 3	Active
DOXOrubicin (75) and Ifosfamide NAdj - Version 3	Active
DOXOrubicin 50mg/m²/DOCEtaxel 75mg/m² (AT 50/75)-21 day cycle - Version 2	Active
DOXOrubicin 75mg/m² Monotherapy - Version 2	Active
DOXOrubicin, and Cyclophosphamide (AC 60/600) - 21 day (00252) - Version 3	Active
DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab (AC-TH) - Version 2	Active
DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T) (00260) - Version 4	Active
Durvalumab Monotherapy 10mg/Kg-14 Day - Version 2	Active
Durvalumab Monotherapy 1500mg – 28 Day - Version 2	Active
EMA/CO Therapy (Etoposide, Methotrexate, DACTINomycin, Cyclophosphamide, vinCRIStine) - Version 2	Active
EMA/EP Therapy (Etoposide Methotrexate DACTINomycin/Etoposide CISplatin) - Version 4	Active
Encorafenib and Binimetinib - Version 1	Inactive
Entrectinib - Version 1	Active
Enzalutamide Monotherapy (00233) - Version 3	Active
EpiRUBicin 75 + Cyclophosphamide (EC75) -21 day - Version 2	Active
EpiRUBicin 90 + Cyclophosphamide (EC90)-21 day - Version 2	Active
EpiRUBicin, CISplatin and 5-Fluorouracil (ECF) - ADJ -21 day - Version 2	Active
EpiRUBicin, CISplatin and 5-Fluorouracil (ECF) -21 day LA/M - Version 2	Active
EpiRUBicin, CISplatin and Capecitabine (ECX) Adj - Version 1	Active
EpiRUBicin, CISplatin and Capecitabine (ECX) LA/M - Version 1	Active
EpiRUBicin, CISplatin and Capecitabine (ECX) NAdj - Version 1	Active
EpiRUBicin, Oxaliplatin and 5-Fluorouracil (EOF)- 21 day - Version 3	Active
epiRUBicin, Oxaliplatin and Capecitabine (EOX) -21 day - Version 4	Active
eriBULin Monotherapy (00228) - Version 3	Active
Erlotinib Monotherapy (00219) - Version 3	Active
Escalated Dose BEACOPP 21 day (00354) - Version 2	Inactive
ESHAP - Version 3	Active
Etoposide and CISplatin 20mg/m² (EP) 5 day - Version 4	Active
Everolimus and Exemestane - Version 2	Active
Everolimus Monotherapy - Version 2	Active
Exemestane Monotherapy Adj - Version 2	Active
Exemestane Monotherapy Met - Version 2	Active
Fedratinib Therapy (00788) - Version 1	Inactive
FLAG Therapy - Version 4	Active
FLAG: Ida 8mg/m² - Version 7	Active
FLOT -14 day NAdj - Version 5	Active
FLOT-14 day Adj - Version 5	Active

Regimen list

Regimen	Status
FLOX - Version 2	Active
Fludarabine & Cyclophosphamide Lymphodepletion for Axicabtagene ciloleucel (Yescarta®) - Version 1	Active
Fludarabine & Cyclophosphamide Lymphodepletion for Tisagenlecleucel (Kymriah®) B-cell ALL - Version 3	Active
Fludarabine & Cyclophosphamide Lymphodepletion for Tisagenlecleucel (Kymriah®) DLBCL - Version 2	Active
Fludarabine, Cyclophosphamide and riTUXimab (FC IV+R) - Version 4	Active
Fludarabine, Cyclophosphamide and riTUXimab (FC Oral +R) - Version 2	Active
Fludarabine,Busulfan,ATG Grafalon® – RIC – MUD - Version 1	Active
Fludarabine,Busulfan,ATG Grafalon® – RIC –SIB - Version 2	Active
Fludarabine,Melphalan,Alemtuzumab-RIC-MUD - Version 1	Active
Fludarabine,Melphalan,Alemtuzumab-RIC-SIB - Version 1	Active
FOLFIRI 14 day (00227) - Version 6	Active
FOLFIRINOX - Version 4	Active
FOLFIRINOX- Rectal Carcinoma - Version 2	Active
FOLFOX-4 14 day Adj (00210.1) - Version 6	Active
FOLFOX-4 14 day Met - Version 4	Active
FOLFOX-6 Modified 14 day Met (00209.2) - Version 9	Active
FOLFOX-6 Modified 14 day Adj (00209.1) - Version 10	Active
FOLFOX-6 Modified Chemoradiation-14 day - Version 4	Active
FOLFOXIRI - Version 4	Active
Fulvestrant - Version 2	Active
Gefitinib Monotherapy - Version 1	Active
Gemcitabine (1000mg/m²) and RT - Version 3	Active
Gemcitabine (1000mg/m²) and Capecitabine (650mg/m²)-21 day - Version 1	Active
Gemcitabine (1000mg/m²) and CARBOplatin (AUC 4) - 21 day - Version 6	Active
Gemcitabine (1000mg/m²) and CARBOplatin (AUC 5)- 21 day - Version 5	Active
Gemcitabine (1000mg/m²) and CISplatin (25mg/m²) - 21 day - Version 3	Active
Gemcitabine (1000mg/m²) and CISplatin (35mg/m²) - 21 day - Version 2	Active
Gemcitabine (1000mg/m²) and CISplatin (70mg/m²) - 21 day - Version 2	Active
Gemcitabine (1000mg/m²) and CISplatin (70mg/m²) Therapy- 28 day - Version 2	Active
Gemcitabine (1000mg/m²) Monotherapy - 28 day Adj (00284.1) - Version 4	Active
Gemcitabine (1000mg/m²) Monotherapy - 28 day Met (00284.2) - Version 4	Active
Gemcitabine (1000mg/m²) Monotherapy - 56 day (00283) - Version 3	Active
Gemcitabine (1000mg/m²), CARBOplatin (AUC 4) and Bevacizumab 15mg/kg - 21 day - Version 5	Active
Gemcitabine (1250mg/m²) and CISplatin (75mg/m²)- 21 day - Version 3	Active
Gemcitabine (1250mg/m²) and CISplatin (80mg/m²) - 21 day - Version 2	Active
Gemcitabine (1250mg/m²) Monotherapy - 21 day - Version 2	Active
Gemcitabine (400mg/m²) and RT - Version 3	Active
Gemcitabine (600mg/m²) and RT-7 day - Version 3	Active
Gemcitabine and CARBOplatin (AUC2) - 21 days - Version 3	Active
Gemcitabine and DOCEtaxel - 21 day - Version 3	Active
Gemtuzumab ozogamicin, DAUNOrubicin and cytarabine (AML induction) - Version 1	Active
Goserelin 10.8mg-12 weeks - Version 3	Active
Goserelin 3.6mg-28 day - Version 2	Active
High Dose Cytarabine - Version 3	Active
High Dose Cytarabine Consolidation Therapy (post R-MPV) - 28 day (00666) - Version 1	Active
High Dose Melphalan Conditioning for Autologous Stem Cell Transplant - Version 2	Active
High dose Methotrexate, high dose Cytarabine, riTUXimab and Thiotepa (MATRix) (00508) - Version 2	Active
Ibrutinib Therapy CLL / Waldenström's macroglobulinaemia - Version 3	Active
Ibrutinib Therapy Mantle Cell Lymphoma - Version 3	Active
ICE (Ifosfamide, CARBOplatin and Etoposide) - Version 3	Active
Idelalisib Monotherapy (00291) - Version 2	Active
Imatinib - GIST Adj - Version 3	Active
Imatinib - GIST Met - Version 2	Active
Inotuzumab ozogamicin Monotherapy - Version 2	Active

Regimen list

Regimen	Status
Intermediate Dose Cytarabine - Version 5	Active
Intrathecal Methotrexate for CNS prophylaxis in GTN - Version 2	Active
Intravenous Vinorelbine Monotherapy - 21 day - Version 3	Active
Ipilimumab Monotherapy - Version 4	Active
Irinotecan 150mg/m² Monotherapy - 28 day - Version 1	Active
Irinotecan Monotherapy - 21 days (00213) - Version 3	Inactive
Ixazomib, Lenalidomide and Dexamethasone- 28 day - Version 2	Active
Lapatinib and Capecitabine - Version 2	Active
Larotrectinib Monotherapy- Adult - Version 1	Active
LEAM Autologous Transplant Conditioning (00468) - Version 4	Active
Lenalidomide 25mg and Dexamethasone- 28 day - Version 1	Active
Lenalidomide Maintenance Therapy (RVD-Lite) - Version 1	Active
Lenvatinib -DTC Therapy - Version 3	Active
Letrozole Monotherapy Adj - Version 4	Active
Letrozole Monotherapy Met - Version 4	Active
Letrozole Monotherapy NAdj - Version 3	Active
Leuprorelin 11.25mg-12 weeks - Version 3	Active
Leuprorelin 22.5mg-12 weeks - Version 3	Active
Leuprorelin 3.75mg-28 days - Version 2	Active
Leuprorelin 30mg-24 weeks - Version 2	Active
Leuprorelin 45mg-24 week - Version 3	Active
Leuprorelin 7.5mg-28 day - Version 2	Active
Lomustine and Bevacizumab 5mg/kg (00742) - Version 1	Active
Lorlatinib - Version 1	Active
Methotrexate 8 day Charing Cross Regimen - Version 2	Active
Methotrexate,vinBLAStine, DOXOrubicin, CISplatin (MVAC) -14 Days - Version 2	Active
Methotrexate,vinBLAStine, DOXOrubicin, CISplatin (MVAC) -28 Days Adj - Version 2	Active
Methotrexate,vinBLAStine, DOXOrubicin, CISplatin (MVAC) -28 Days Met - Version 2	Active
Methotrexate,vinBLAStine, DOXOrubicin, CISplatin (MVAC) -28 Days NAdj - Version 2	Active
Midostaurin (DAUNOrubicin and Cytarabine) Induction Therapy - Version 1	Active
Midostaurin and Intermediate Dose Cytarabine Consolidation Therapy (00683) - Version 3	Active
Midostaurin Maintenance - Version 1	Active
Mifamurtide - Version 1	Inactive
mitoMYcin and Capecitabine Chemoradiation (00727) - Version 2	Active
Modified CyBorD/ Bortezomib, Cylophosphamide and Dexamethasone – Weekly Therapy - Version 3	Active
Modified FOLFIRINOX - Version 2	Active
nab-PACLitaxel and Gemcitabine - 28 day (00256) - Version 3	Active
nab-PACLitaxel Monotherapy– 21 day - Version 2	Active
nab-PACLitaxel Weekly Monotherapy–28 day (00736) - Version 2	Active
Neoadjuvant DOCEtaxel, CISplatin,5-Fluorouracil and Chemoradiation and Surgery - Version 4	Active
Neratinib - Version 1	Active
Nintedanib - Version 1	Active
Niraparib Monotherapy - Version 1	Active
Nivolumab 1mg/kg Ipilimumab 3mg/kg - Version 3	Active
Nivolumab 3mg/kg with Ipilimumab 1mg/kg - Version 2	Active
Nivolumab Monotherapy 240mg - 14 days - Version 6	Active
Nivolumab Monotherapy 240mg - 14 days Adj (26 cycles) - Version 4	Active
Nivolumab Monotherapy 480mg-28 days - Version 5	Active
Nivolumab Monotherapy 480mg-28 days Adj (13 cycles) - Version 4	Active
Nivolumab, ipilimumab, CARBOplatin and PACLitaxel - Version 2	Active
Nivolumab, ipilimumab, PEMEtrexed and CARBOplatin (AUC 5) - Version 2	Active
Nivolumab, ipilimumab, PEMEtrexed and CARBOplatin (AUC 6) - Version 2	Active
Nivolumab, ipilimumab, PEMEtrexed and CISplatin - Version 1	Active
Nordic Therapy - Version 1	Active
Obinutuzumab and Bendamustine-28 day cycle - Version 4	Active
Obinutuzumab and Chlorambucil - Version 2	Active

Regimen list

Regimen	Status
Obinutuzumab and CHOP-21 day - Version 3	Active
Obinutuzumab Cyclophosphamide vinCRIStine and prednisoLONE (O-CVP)-21 days - Version 3	Active
Obinutuzumab Maintenance Therapy-56 day - Version 4	Active
Olaparib (Capsule) Monotherapy - Version 2	Active
Oral Etoposide - Version 3	Active
Oral Vinorelbine Monotherapy-7 days - Version 4	Active
Osimertinib Monotherapy - Version 1	Active
PACLitaxel (80) and Trastuzumab-7 day (12 weeks) - Version 3	Active
PACLitaxel 80mg/m² Day 1, 8 and 15 Monotherapy-28 Day (00621) - Version 3	Active
PACLitaxel Monotherapy 80mg/m² Day 1, 8, 15 and 22 – 28 Day (00226) - Version 9	Active
PACLitaxel/CISplatin alternating with PACLitaxel/Etoposide (TP/TE) - Version 2	Active
Palbociclib-28 day - Version 3	Active
Panitumumab 6mg/kg (00225) - Version 4	Active
Panitumumab 6mg/kg and FOLFIRI -14 day - Version 4	Active
Panitumumab 6mg/kg and Modified FOLFOX-6 – 14 day - Version 5	Active
PAZOPanib - Version 1	Active
Pegylated Liposomal DOXOrubicin 20 mg/m² (CAELYX)® 21 days - Version 3	Active
Pegylated Liposomal DOXOrubicin 50mg/m² (CAELYX) 28 days - Version 4	Active
Pembrolizumab 200mg and Axitinib (00583) - Version 1	Active
Pembrolizumab 200mg Monotherapy (00455.1) - Version 9	Active
Pembrolizumab 200mg Monotherapy Adj (18 cycles) (00455.2) - Version 6	Active
Pembrolizumab 400mg Monotherapy (00558.1) - Version 9	Active
Pembrolizumab 400mg Monotherapy Adj (9 cycles) (00558.2) - Version 6	Active
Pembrolizumab, CARBOplatin (AUC 5) and 5-Fluorouracil Therapy (00705) - Version 2	Active
Pembrolizumab, CISplatin and 5-Fluorouracil (00706) - Version 2	Active
Pembrolizumab, PACLitaxel and CARBOplatin (AUC 6) (00579) - Version 5	Active
Pembrolizumab, PEMEtrexed and CARBOplatin (AUC 5) (00568) - Version 4	Active
Pembrolizumab, PEMEtrexed and CISplatin (00569) - Version 2	Active
PEMEtrexed and CARBOplatin - Version 6	Active
PEMEtrexed and CISplatin - Version 3	Active
PEMEtrexed Monotherapy (00222) - Version 3	Active
Pertuzumab and Trastuzumab (Continuation) - Version 2	Active
Pertuzumab and Trastuzumab (Phesgo®) and DOCEtaxel - 21 day cycle (00796) - Version 1	Active
Pertuzumab and Trastuzumab (Phesgo®) Maintenance Therapy - Version 1	Active
Pertuzumab and Trastuzumab and Chemotherapy - 21 day cycle Adj (00350.2) - Version 4	Active
Pertuzumab and Trastuzumab and Chemotherapy - 21 day cycle NAdj (00350.1) - Version 4	Active
Pertuzumab and Trastuzumab and DOCEtaxel Therapy - 21 day (00204) - Version 5	Active
Pertuzumab Trastuzumab and Vinorelbine - Version 3	Active
Pertuzumab Trastuzumab and Weekly PACLitaxel - 21 day cycle - Version 4	Active
Pertuzumab/Trastuzumab (Phesgo®) and Weekly PACLitaxel - 21 day - Version 1	Active
Pertuzumab/Trastuzumab (Phesgo®), PACLitaxel and CARBOplatin (TRAIN-2) - Version 1	Active
Pixantrone Therapy - Version 3	Active
Polatuzumab Vedotin, Bendamustine and riTUXimab - Version 2	Active
Pomalidomide and Dexamethasone - Version 3	Active
PONATinib - Version 1	Active
Procarbazine Lomustine and vinCRIStine (PCV) - Version 4	Active
Procarbazine, Lomustine and vinCRIStine (PCV) Therapy – 56 days - Version 1	Active
QUASAR (Modified) Fluorouracil (370mg/m²) and Folinic Acid (50mg) Weekly Adj - Version 5	Active
QUASAR (Modified) Fluorouracil (370mg/m²) and Folinic Acid (50mg) Weekly Met - Version 4	Active

Regimen list

Regimen	Status
R- miniCHOP - 21 days (00436) - Version 3	Active
R-CEOP – 21 days - Version 3	Active
R-CHOP - 21 days - Version 6	Active
R-CHOP-14 days - Version 7	Active
R-CODOX-M (Patients >65 years) - Version 2	Active
R-CODOX-M (Patients ≤65yrs) - Version 2	Active
R-DHAP - Version 2	Active
Regorafenib Monotherapy (00244) - Version 3	Active
R-ESHAP - Version 5	Active
R-Gemcitabine (1000mg/m²) Oxaliplatin - 14 day - Version 2	Active
Ribociclib-28 day - Version 1	Active
R-ICE (riTUXimab), Ifosfamide, CARBOplatin and Etoposide) - Version 6	Active
riTUXimab (S/C 1400mg) Maintenance - 56 day - Version 3	Active
riTUXimab (S/C 1400mg) Maintenance - 84 day - Version 3	Active
RiTUXimab 375 mg/m² - 7 day - Version 2	Active
riTUXimab 375 mg/m² Combination Therapy-21 day - Version 3	Active
RiTUXimab 375 mg/m² Maintenance Therapy- 56 day - Version 3	Active
RiTUXimab 375mg/m² - Follicular Lymphoma (every 2 months) - Version 2	Inactive
RiTUXimab 375mg/m² - Follicular Lymphoma (every 3 months) - Version 2	Inactive
RiTUXimab 375mg/m² - Follicular Lymphoma (once weekly for four weeks) - Version 2	Inactive
RiTUXimab 375mg/m² Maintenance-84 day - Version 3	Active
RiTUXimab and Bendamustine - Version 3	Active
riTUXimab S/C, (R-CHOP) Therapy– 21 Days - Version 1	Active
riTUXimab Gemcitabine, Dexamethasone and ClSplatin ((R**)-GDP) - Version 2**	Active
riTUXimab, Methotrexate, Procarbazine and vinCRIStine (R-MPV) – 14 Days Induction (00664) - Version 1	Active
riTUXimab-HyperCVAD (MCL) – Part A (00466) - Version 1	Active
riTUXimab-Methotrexate and Cytarabine Therapy (MCL) - Hyper CVAD Part B (00467) - Version 1	Active
R-IVAC (Patients >65 years) - Version 2	Active
R-IVAC (patients ≤ 65 years) - Version 2	Active
Roswell Park Modified (Fluorouracil 500mg/m² and Folinic Acid 50mg weekly x 6) Regimen Adj - Version 4	Active
Roswell Park Modified (Fluorouracil 500mg/m² and Folinic Acid 50mg weekly x 6) Regimen Met - Version 4	Active
Ruxolitinib Monotherapy - Version 2	Active
Siltuximab Monotherapy - Version 2	Active
SORAfenib - Version 2	Active
SUNitinib 37.5mg - Version 1	Active
SUNitinib 50mg - Version 1	Active
Talazoparib - Version 1	Active
Tamoxifen Monotherapy Adj - Version 2	Active
Tamoxifen Monotherapy Met - Version 2	Active
Temozolomide Recurrent Therapy - Version 2	Active
Temozolomide with Radiotherapy (RT) and Adjuvant Therapy - Version 2	Active
Temozolomide with Radiotherapy (RT) and Adjuvant Therapy - Patients greater than 65 years - Version 2	Active
Temsirolimus Monotherapy - Version 3	Active
TESTING Regimen - Version 1	Active
Topotecan Monotherapy – 5 day - Version 3	Active
Topotecan Monotherapy – Weekly - Version 3	Active
Topotecan Oral Monotherapy - Version 2	Active
Trabectedin and Pegylated Liposomal DOXOrubicin (PLD) - Version 3	Active
Trabectedin Monotherapy - Version 2	Active
Trametinib and Dabrafenib Adj - Version 1	Active
Trametinib and Dabrafenib Met - Version 2	Active
Transcription only. See original prescription. - Version 1	Active
Trastuzumab (IV) Monotherapy - 21 days Adj (00200.1) - Version 6	Active
Trastuzumab (IV) Monotherapy - 7 days - Version 4	Active
Trastuzumab (IV) Monotherapy- 21 days Met (00200.2) - Version 6	Active

Regimen list

Regimen	Status
Trastuzumab 5-Fluorouracil and CISplatin - 21 days - Version 4	Active
Trastuzumab and FOLFOX-6 Modified - 14 day - Version 3	Active
Trastuzumab Emtansine (Kadcyla®) - 21 days (00206) - Version 4	Active
Trastuzumab Emtansine (Kadcyla®) Early Breast Cancer Therapy- 21 days (00659) - Version 2	Active
Trastuzumab Subcutaneous 21 days - Metastatic Breast Cancer (00272) - Version 6	Active
Trastuzumab Subcutaneous 21 days - Early Breast Cancer (00285) - Version 6	Active
Tretinoin (ATRA) with Arsenic Trioxide (ATO) Consolidation - Version 2	Active
Tretinoin (ATRA) with Arsenic Trioxide (ATO) Induction - Version 2	Active
Tretinoin (ATRA/IDArubicin (PETHEMA AIDA) Induction: High Risk (00366) - Version 2	Active
Triptorelin 11.25mg-12 weeks - Version 2	Active
Triptorelin 22.5mg-24 weeks - Version 2	Active
Triptorelin 3mg-28 day - Version 1	Active
Two Day Etoposide CISplatin (EP) - Version 2	Active
Vandetanib Therapy (00242) - Version 3	Active
Vemurafenib Monotherapy (00102) - Version 3	Active
Venetoclax and Obinutuzumab - Version 2	Active
Venetoclax and riTUXimab Therapy - Version 1	Active
Venetoclax Monotherapy - Version 2	Active
VinBLAStine and Methotrexate - Version 2	Active
Vinorelbine 30 (Day 1,8,15) and CISplatin 80 (Day1) Therapy- 21 day - Version 2	Active
Vinorelbine and CISplatin Therapy - 28 day - Version 2	Active
Vismodegib Monotherapy - Version 3	Active
Vyxeos liposomal® (DAUNOrubicin and cytarabine) Consolidation - Version 2	Active
Vyxeos liposomal® (DAUNOrubicin and cytarabine) Induction - Version 1	Active
Weekly CARBOplatin (AUC2) PACLitaxel 50mg/m² with Radiotherapy - Version 7	Active
Zanubrutinib - Version 1	Active
Zoledronic Acid -28 days - Version 1	Active
Zoledronic Acid- 3 monthly - Version 2	Active
Zoledronic Acid- 6 monthly - Version 2	Active
Zoledronic Acid Monotherapy (00545) - Version 4	Active